NCT04595162View on ClinicalTrials.gov

A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2035

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

GC019F

GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.

Sponsors
All Listed Sponsors
collaborator

Gracell Biotechnology Ltd.

OTHER

lead

Peking University Third Hospital

OTHER

NCT04595162 - A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | Biotech Hunter | Biotech Hunter